Navigation Links
Lev Pharmaceuticals Invites You to Participate in its Q3'07 Earnings Results Conference Call and Webcast
Date:11/9/2007

t demonstrate the potential to address unmet medical needs. Lev is also evaluating the development of C1 inhibitor for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

Contact:

Jason Tuthill

Lev Pharmaceuticals, Inc.

Director, Investor Relations

(212) 850-9130

jtuthill@levpharma.com


'/>"/>
SOURCE Lev Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 2015 , ... Costello served as Lead Levee Design Engineering Manager for a ... Texas area from future storm surge flooding, such as occurred in Hurricane Ike in ... alternatives for providing protection, Costello also balanced socio-economic and environmental needs and ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... making good progress in evaluating the full range of capabilities of its unique ... tissue stem cells perform the day-to-day renewal and repair of normal tissues and ...
(Date:7/28/2015)... LONDON , July 29, 2015 ... on acquiring, rapidly developing and commercialising ... human health   Highly experienced management team; ...     Mereo BioPharma Group Ltd ... successfully raised $119m ( c. £76.5m), gross, from blue ...
(Date:7/28/2015)... ... ... The new Xsample 530 sample changer for vials can be used with Anton ... from less than 12,000 mPas (internal air) up to 36,000 (external air) – and can ... eye about Xsample 530 is its removable magazine, which is easily lifted off its hub ...
Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11New Moves in Automatic Sample Handling: Introducing Xsample 530 2
... Feb. 28, 2012 MiMedx Group, Inc. (OTCBB: MDXG), ... regenerative biomaterials and bioimplants processed from human amniotic membrane, ... 31, 2011. Full Year 2011 ResultsThe ... 31, 2011, with revenue of $7.8 million, a tenfold ...
... Professor Dr. Manfred T. Reetz honored for ... Elsevier , a world-leading provider of scientific, ... that leading German scientist, Professor Dr. Manfred T. ... Hans Meerwein Research Professor at Philipps-Universität, Marburg, has ...
... a critical care company focused on developing and commercializing ... it has enrolled the last patient into its Pivotal ... oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD).  ... last patient six weeks ahead of schedule. The trial ...
Cached Biology Technology:MiMedx Group Announces 2011 Results 2MiMedx Group Announces 2011 Results 3MiMedx Group Announces 2011 Results 4MiMedx Group Announces 2011 Results 5MiMedx Group Announces 2011 Results 6MiMedx Group Announces 2011 Results 7MiMedx Group Announces 2011 Results 8Leading German Researcher Awarded Elsevier's 2011 Tetrahedron Prize 2Leading German Researcher Awarded Elsevier's 2011 Tetrahedron Prize 3Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia 2Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia 3Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia 4
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015  Synaptics ... interface solutions, announced today that it will report financial ... on Thursday, July 30, 2015 after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... In scientific publishing, how much reuse of text ... Institute at Virginia Tech and collaborators have shown that ... publication practices from thousands of full-text papers in the ... process is to find out what is restated before ...
... SAN DIEGO (October 25, 2010) Klaus ... for Allergy & Immunology, was recently awarded the prestigious ... Paris, France. A lifetime achievement award presented by ... honor in recognition of his pioneering endeavors in vascular ...
... to their feathers to stand out and attract mates, according ... Biolgica de Doňana in Seville, Spain, and colleagues. Their research ... pigments (carotenoids) from the secretions of their uropygial gland for ... the majority of birds and is situated near the base ...
Cached Biology News:Plagiarism sleuths tackle full-text biomedical articles 2La Jolla Institute scientist Klaus Ley receives Malpighi award 2La Jolla Institute scientist Klaus Ley receives Malpighi award 3Beauty from the bottom up 2